Abstract:Objective To explore the method of preparation of 99m Tc labeled Anti-VEGF McAb 5-FU loaded polylactic acid nanoparticles ( 99m Tc-5-Fu-Ab-NPs), and investigate the biological distribution of the nanoparticles in human gastric carcinoma xenografts. Methods Anti-VEGF monoclonal antibodyes (MCAB) in 5-FU-Ab-NPs were labeled with 99m Tc using a modified Schwarz method. After isolation of the 99m Tc-5-FU-Ab-NPs using a Sephadex G-250 column, the labeling percentage and radiochemical purity were determined using paper chromatography. The immunocompetence of the 99m Tc-5-FU-Ab-NPs as tumor markers was determined using ELISA and immunohistochemistry. 99m Tc-5-FU-Ab-NPs (experimental group), 99m Tc-labelled murine multiclonal IgG loaded polylactic acid and nanoparticles (control group) were injected via the tail vein into SCID mice bearing human gastric carcinoma. A radio-immunity ECT image was developed at 2 and 6 h after the injection. Following the ECT imaging, the mice were sacrificed, their tissue and tumor radioactivity distribution determined, and percentage of the injected-dose per gram (%ID/g) and tumor/nontumor (T/NT) ratio calculated. High performance liquid chromatography (HPLC) was used to determine the 5-FU concentration in the tumor tissue and blood in the mice of both groups. Results The percentage of 99m Tc-5-FU-Ab-NPs labeling was 90%∼95%. There was no obvious decrease in the antibody activity before and after labeling. The radio-immuno-imaging (RII) showed that the tumor image had developed 2 h after injection of the 99m Tc-5-FU-Ab-NPs, and with time it was clearer at the 6th hour following the injection. The %ID/g of the tumor tissue at both 2 h and 6 h after the injection was significantly higher compared to the control group. The tumor %ID/g and the tumor to blood activity ratio (TB) of the experimental group at 6 h following the injection increased compared to that at 2 h, and at the same time, 5-FU concentration in the tumor of the experimental group continuously increased over time, and showed a significant difference compared to the 5-FU concentration in the tumor of the control group. Conclusion The 99m Tc-5-FU-Ab-NPs prepared in this study are adequate to meet the demands of the RII, and the immune targeting ability of the anti-VEGF MCAB is reliable. Six hours after injection, the 99m Tc-5-FU-Ab-NPs showed a relatively high specific concentration shadow in the human gastric carcinoma xenografts.

Study on 9 9mTc-C50-F(ab′)2 Using Radio Immunoscintigraphy for Ovarian Carcinoma

EXPERIMENTAL STUDY OF RADIOIMMUNOIMAGING WITH~(99m)Tc LABELING F(ab’)2 FRAGMENT

Radioimmunoimaging of <sup>131</sup>i Labeled ScFv in Nude Mice of Ovarian Cancer

Studies of 99mTc labeled carcinoembyronic antigen monoclonal antibody C50 fragment Fab' and biodistrobution

Radioimmunoimaging of 153Sm labeled anti-H-OV-5ScFv in nude mice of ovarian cancer

Experimental Study of Radioimmunoimaging on the Nude Mice Bearing Human Ovarian Carcinoma by ~(99M)tc-Coc183b_2

Radioimmunoimaging and Biodistribution of ~(131)I Labeled Anti-Cea Monoclonal Antibody C50 in Nude Mice Bearing Human Breast Carcinoma Xenografts

Biokinetics of 131 I-labelled Monclonal Antibodies Against CEA in Ovarian Cancer Patients

Studies on the distribution and radioimmunoimaging of 99m Tc-labeled 5-fluorouracil loaded immunological nanoparticles in tissues and human gastric carcinoma xenografts

Studies on the Distribution and Radioimmunoimaging of 99mTc-Labeled 5-Fluorouracil Loaded Immunological Nanoparticles in Tissues and Human Gastric Carcinoma Xenografts

Positron Emission Tomography Imaging of Tumor Angiogenesis with a (61/64)Cu-Labeled F(ab')(2) Antibody Fragment.

Radioimmunolocalization and blodistribution of 131Ⅰ labeled anti-CEA,TPS and mixture monoclonal antibody in nude mice bearing human breast cancer xenografts

Local Radioimmunotherapy of Breast Cancer-Bearing Nude Mice Using Anti-Cea Monoclonal Antibody C50 Labeled with 131I

Radioimmunoimaging of ovarian cancer with 131 I labeled CEA monoclonal antibody

Preliminary Application of 99Mtc-Labeled Anti-Cea Monoclonal Antibody Kit

STUDY OF RADIOIMMUNOIMAGING WITH MONOCLONAL ANTIBODY AGAINST THE PATIENTS WITH SCLC

Radioimmunotherapy of human colon cancer xenografts with 131I-labeled anti-CEA monoclonal antibody.

Radioimmunotherapy of Human Colon Cancer Xenografts with<sup>131</sup>I-Labeled Anti-CEA Monoclonal Antibody

Fractionated Radioimmunotherapy Using Low Doses of Iodine-131 Labeled Anti-Cea Monoclonal Antibody after Tumor Volume Reduction.

Radioimmunotherapy Of Human Colon Cancer Xenografts With I-131-Labeled Anti-Cea Monoclonal Antibody

Initial Evaluation of 99m Tc-labeled Anti-Carcinoembryonic Antigen Single-Chain Fragment Variable for Micro-Single-photon Emission Computed Tomography Imaging in Mice with Colorectal Cancer.